VIDYAMOHAN BALU: Open Payments
NPI 1265815880 · SAN JACINTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$341 in 15 payments from 10 companies in 2025. Trend: 2023 $410 · 2024 $654 · 2025 $341
Food & beverage: $341
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $95 |
| Novo Nordisk Inc | 2 | $53 |
| Lilly USA, LLC | 2 | $49 |
| Ardelyx, Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $24 |
| GENZYME CORPORATION | 1 | $24 |
| Viatris Specialty LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| SHIELD THERAPEUTICS INC | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: MOUNJARO, VRAYLAR, Ozempic, QULIPTA, IBSRELA, FREESTYLE LIBRE 3, DUPIXENT, YUPELRI.
Industry payments across CA — which companies pay providers there.
